Is the fatality rate high in Dramani/Derba? Are there risks?

Delamanid/Delamanid is an innovative drug that has attracted attention in the treatment of drug-resistant tuberculosis in recent years. Its application has filled some gaps in the treatment of multi-drug-resistant tuberculosis. As a nitroimidazole antituberculosis drug, delamanid plays a role in inhibiting cell wall synthesis of Mycobacterium tuberculosis, showing unique advantages especially in drug-resistant cases. However, while patients are concerned about the efficacy of the drug, they are also often concerned about its safety, especially the focus of whether it will bring about a high fatality rate. In fact, as a new drug, the overall safety of delamanid has been fully studied and confirmed in international clinical applications.

In terms of pharmacological mechanism of action, delamanid inhibits the synthesis of methoxy-ergosterol in Mycobacterium tuberculosis, causing damage to the cell wall structure, thereby killing the pathogen. This specific target determines that the drug has a strong effect on tuberculosis bacteria but has less direct damage to human cells. Therefore, from a pharmacological basis, delamanid is not a drug with a high risk of death. However, the practical use of any prescription drug carries risks of adverse reactions, especially in the context of long-term combined use.

In global application data, the main risk of delamanid is electrocardiogramQT interval prolongation, which may cause abnormal heart rhythm in some patients, but in most cases serious consequences can be avoided through monitoring and dose adjustment. It is unusual for a high fatality rate to be directly caused by the drug itself. What needs more attention is that delamanid is often not used alone, but in combination with other anti-tuberculosis drugs to form a multi-drug regimen. During this combination, some drug-drug interactions may increase cardiotoxicity or liver burden, which is also the focus of risk management.

Reference: https://go.drugbank.com/drugs/DB11637